Reactive Oxygen Species in Cardiometabolic Syndrome, Neuronal Diseases and Cancer : From Bench to Its Potential Therapeutics.

Format:

Book

Author/Creator:

Isenovic, Esma.

Contributor:

Suri, M. B. A.

Language:

English

Physical Description:

1 online resource (453 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier, 2025.

Summary:

Reactive Oxygen Species in Cardiometabolic Syndrome, Neuronal Diseases and Cancer: From Bench to its Potential Therapeutics systematically summarizes findings concerning the biochemical properties of various reactive oxygen species (ROS).

Contents:

Front Cover

Halftitle

Titlepage

Copyright

Contents

Contributors

Preface

Section I Introduction to ROS

Chapter 1 Reactive oxygen species in general

1.1 Introduction

1.2 The basics of oxidative stress

1.3 Cellular sources of free radicals

1.4 Mitochondrial ROS production

1.5 Exogenous sources of ROS

1.6 Mechanisms of ROS-induced oxidative damage

1.7 Antioxidant defense

1.7.1 Enzymatic antioxidants

1.7.2 Nonenzymatic antioxidants

1.8 Natural antioxidant compounds in preventing os stress in various diseases

1.9 Conclusion and future perspectives

Funding

References

Chapter 2 Reactive oxygen species signaling

2.1 Introduction to ROS signaling

2.2 Mechanisms of ROS signaling

2.3 ROS-activated signaling pathways

2.3.1 MAPK pathway

2.3.2 PI3K/Akt pathway

2.3.3 NFκB pathway

2.3.4 Other ROS-regulated signaling pathways

2.4 Ion channels targeted by ROS

2.5 ROS and disease pathology

2.5.1 Cancer

2.5.2 Cardiovascular diseases

2.5.3 Neurodegenerative diseases

2.6 Therapeutic targeting of ROS signaling

2.7 Modulation of redox-sensitive pathways

2.8 Conclusion and future perspectives

Acknowledgment

Chapter 3 ROS and regulation of gene expression

3.1 Introduction to ROS and regulation of gene expression

3.2 ROS

3.2.1 Defining ROS and cellular sources

3.2.2 Redox signaling - mechanisms of action in gene regulation

3.2.3 Disturbed redox homeostasis

3.3 ROS: Signaling molecules and regulators of gene expression

3.3.1 ROS and redox-sensitive transcription factors

3.4 ROS and regulation of gene expression in human diseases

3.4.1 ROS and regulation of gene expression in cancer

3.4.2 ROS and regulation of gene expression in cardiovascular diseases.

3.4.3 ROS and regulation of gene expression in neurodegenerative diseases

3.4.4 ROS and regulation of gene expression in metabolic disorders

3.5 Conclusions and future perspectives

Abbreviations

Section II ROS in cardiometabolic syndrome

Chapter 4 Molecular mechanisms of reactive oxygen species effects in cardiometabolic syndrome

4.1 Introduction

4.2 Clinical criteria for CMS and its prevalence

4.3 Key epigenetic mechanisms in CMS

4.3.1 Altered DNA methylation patterns

4.3.2 Histone modifications in CMS

4.3.3 Role of microRNAs and long non-coding RNAs in CMS

4.4 Genetic profile in CMS

4.4.1 Single nucleotide polymorphisms in CMS

4.4.2 Copy number variations in CMS

4.5 Transcription factors in CMS

4.6 Key signal transduction pathways altered in CMS

4.7 Adipokines, growth factors, and other hormone signaling in CMS

4.8 Oxidative stress in CMS

4.8.1 Effect of elevated ROS on metabolic function

4.8.2 Oxidative modification of biomolecules

4.9 Hyperlipidemia and oxidative stress in CMS

4.9.1 LDL Metabolism and oxidative stress in CMS

4.10 Conclusion

Chapter 5 Molecular mechanisms of reactive oxygen species and regulation of gene expression in cardiometabolic syndrome

5.1 Introduction

5.2 Molecular mechanisms of ROS and regulation of gene expression related to the development of IR

5.3 Molecular mechanisms of ros and regulation of gene expression related to pancreatic beta cell dysfunction

5.4 Molecular mechanisms of ROS and regulation of gene expression related to the development of hypertension

5.5 Molecular mechanisms of ROS and regulation of gene expression in endothelial dysfunction and dyslipidemia

5.6 Molecular mechanisms of ROS and regulation of gene expression related to the development of obesity

5.7 Conclusions.

5.8 Future perspectives

Chapter 6 Antioxidant supplementation and cardiometabolic syndrome

6.1 Introduction

6.2 Antioxidant strategies

6.3 Antioxidant supplementation

6.3.1 Antioxidant supplementation in obesity

6.3.2 Antioxidant supplementation in polycystic ovary syndrome

6.3.3 Antioxidant supplementation in metabolic dysfunction-associated steatotic liver disease

6.3.4 Antioxidant supplementation in arterial hypertension

6.3.5 Antioxidant supplementation in T2DM

6.3.6 Antioxidant supplementation in cardiovascular disease

6.3.7 Antioxidant supplementation in chronic kidney disease

6.4 Lifestyle interventions

6.5 Conclusion and future perspectives

Section III ROS and neuronal diseases

Chapter 7 Molecular mechanisms of reactive oxygen species in neurodegenerative diseases (Alzheimer, Parkinson, etc.)

7.1 Introduction

7.1.1 Alzheimer's disease

7.1.2 Parkinson's disease

7.1.3 Amyotrophic lateral sclerosis

7.1.4 Huntington's disease

7.2 Conclusion and future directions

Chapter 8 Reactive oxygen species and psychiatric disorders

8.1 Introduction

8.2 ROS in depression and anxiety

8.3 ROS and bipolar disorder

8.4 ROS and post-traumatic stress disorder

8.5 ROS and schizophrenia

8.5.1 The role of inflammation and ROS in schizophrenia

8.5.2 Dopaminergic signaling and ros formation

8.6 ROS and autism spectrum disorder

8.6.1 The role of inflammation and ros in autism spectrum disorder

8.6.2 Inhibition of superoxide dismutase activity

8.6.3 The mTORC1 pathway and ROS in autism spectrum disorder

8.7 Conclusions

8.7.1 Future perspectives

Chapter 9 The role of antioxidant supplementation in neuronal disorders

9.1 Introduction

9.2 Oxidative stress, as canonically known, initiates neuronal damage.

9.3 Oxidative stress suggested autophagy pathway activation (in the Brain)

9.4 Oxidative stress suggested mitophagy pathway activation

9.5 Oxidative stress suggested ferritinophagy pathway activation

9.6 Oxidative stress suggested macrophage polarization activation

9.7 Oxidative stress could result in different types of neuronal cell death

9.8 Oxidative stress and brain-heart cross-talk

9.9 Antioxidant mechanisms and neuronal diseases

9.10 Recommendations and future prospective

Section IV ROS and cancer

Chapter 10 Reactive oxygen species (ROS) and early stage of cancer (Cancer development)

10.1 Introduction

10.2 Redox homeostasis and regulation

10.3 Major sources of ROS and mechanisms of ROS generation in precancerous cells

10.3.1 The mitochondrial electron transport chain

10.3.2 Peroxisomal metabolism

10.3.3 Endoplasmic reticulum

10.3.4 NADPH oxidases

10.3.5 Xanthine oxidase

10.3.6 Cyclooxygenase

10.3.7 Lipoxygenases

10.3.8 Extracellular and environmental sources

10.4 ROS in early tumorigenesis

10.5 ROS in oncogenic transformation

10.6 ROS and epigenetic alterations in cancer initiation

10.7 ROS in cell proliferation and apoptosis resistance

10.8 Conclusions and future remarks

Chapter 11 Reactive oxygen species (ROS) and late-stage cancer (Cancer metastasis)

11.1 Introduction

11.1.1 The mechanisms by which ROS affects cancer metastasis

11.1.2 The role of ROS in cell migration

11.1.3 The role of ROS in cancer invasion

11.1.4 The role of ROS in EMT

11.1.5 The role of ROS in angiogenesis

11.1.6 The role of tumor-suppressor genes in ROS-mediated cancer metastasis

11.1.7 The role of microRNAs in ROS-mediated cancer metastasis

11.2 The role of ROS in liver cancer progression and metastasis.

11.2.1 The main risk factors in developing HCC

11.2.2 ROS in HCC genetic changes

11.2.3 ROS in HCC

modifications of signaling pathways

11.2.4 ROS and transcription factors in HCC

11.2.5 ROS and autophagy

11.2.6 Cholangiocarcinoma

11.2.7 ROS and inflammation in CCA

11.2.8 Angiosarcoma and hepatoblastoma

11.3 The role of ROS in CRC progression and metastasis

11.3.1 ROS-mediated ECM remodeling and migration in CRC

11.3.2 ROS-mediated EMT in CRC

11.3.3 ROS-mediated angiogenesis in CRC

11.3.4 The role of tumor-suppressor genes in ROS-mediated progression of CRC

11.3.5 ROS-mediated regulation of MicroRNAs in CRC

11.4 The role of ROS in BC progression and metastasis

11.5 Conclusion and future directions

Acknowledgments

Conflict of interest

Chapter 12 Antioxidant supplementation and cancer

12.1 Introduction

12.2 Role of enzymatic and non-enzymatic endogenous antioxidants in cancer

12.3 Role of non-enzymatic endogenous antioxidants in cancer

12.4 Dietary antioxidants in cancer

12.5 Conclusions

12.6 Future perspectives

Chapter 13 Summary with concluding remarks, and future perspective

13.1 Summary

13.2 Concluding remarks

13.3 Future perspectives

Index

Back Cover.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

0-443-27334-0

OCLC:

1532833808